JPMorgan Chase & Co. Trims Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

JPMorgan Chase & Co. lessened its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 22.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 577,129 shares of the biotechnology company’s stock after selling 170,402 shares during the quarter. JPMorgan Chase & Co. owned 0.28% of BioCryst Pharmaceuticals worth $4,386,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of BioCryst Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock worth $57,000 after buying an additional 1,322 shares during the last quarter. DRW Securities LLC acquired a new position in BioCryst Pharmaceuticals in the second quarter valued at approximately $74,000. Xponance Inc. boosted its position in BioCryst Pharmaceuticals by 13.1% in the 2nd quarter. Xponance Inc. now owns 12,980 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 1,505 shares in the last quarter. Quantinno Capital Management LP acquired a new stake in shares of BioCryst Pharmaceuticals during the 3rd quarter worth approximately $82,000. Finally, SkyView Investment Advisors LLC increased its holdings in shares of BioCryst Pharmaceuticals by 30.0% during the 3rd quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 3,000 shares in the last quarter. 85.88% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Trading Up 5.5 %

BCRX stock opened at $7.45 on Friday. The stock has a market cap of $1.54 billion, a P/E ratio of -12.21 and a beta of 1.76. BioCryst Pharmaceuticals, Inc. has a twelve month low of $4.03 and a twelve month high of $8.88. The company’s 50 day moving average is $7.57 and its two-hundred day moving average is $7.61.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.07). The business had revenue of $117.10 million for the quarter, compared to analysts’ expectations of $113.99 million. During the same quarter last year, the business posted ($0.19) earnings per share. The business’s revenue was up 35.1% on a year-over-year basis. On average, equities research analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current year.

Wall Street Analysts Forecast Growth

BCRX has been the subject of a number of analyst reports. Barclays upped their price objective on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Evercore ISI upped their price target on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Finally, Needham & Company LLC upped their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.17.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.